Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group Limited has announced that its Tacrolimus Extended-release Capsules have received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in the area of immunological rejection, potentially strengthening its market position and offering new treatment options for graft rejection in kidney and liver transplant patients.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company engaged in the pharmaceutical industry, primarily focusing on the development, manufacturing, and sale of pharmaceutical products. The company is known for its diverse range of products, including those in the therapeutic area of immunological rejection.
YTD Price Performance: 101.99%
Average Trading Volume: 171,345,986
Technical Sentiment Signal: Buy
Current Market Cap: HK$109.6B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.